Naomi Fujioka, MD
While durvalumab (Imfinzi) has become standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC) who do not progress following platinum-based chemoradiation, investigators are continuing to evaluate the optimal timing and sequencing of immunotherapies, and to tease out subsets who will benefit most from these approaches, explained Naomi Fujioka, MD.
Data from the initial analysis of the PACIFIC trial showed a 48% reduction in the risk of progression or death versus placebo, leading to the February 2018 FDA approval of durvalumab for patients with locally advanced, unresectable disease who have not progressed following concurrent chemoradiotherapy.1
In July 2019, the FDA updated the label for durvalumab to include 3-year overall survival (OS) data, which showed a 31% reduction in the risk of death versus placebo.2
"The PACIFIC trial [showed the benefit of giving] immunotherapy after chemoradiation. There are all kinds of ongoing studies that are trying to determine where immunotherapy fits in," said Fujioka. "There's one interesting trial being done right now where patients are being randomized to receive [concurrent] immunotherapy and chemoradiation, immunotherapy halfway through chemoradiation, or immunotherapy following chemoradiation, as in the PACIFIC trial."
... to read the full story